DOTAP/DC-CHOL Cationic Liposomes
Product code:F50101V
Lipid composition: DOTAP/DC-Cholesterol (50:50 mol/mol)
Mean particle size:50-80 nm (by DSL)
Lipid concentration: 40 mM (24.7 mg/mL)
Volume:2.0mL
Bulk solution:D5W (dextrose in milli-Q water)
Shelf-life:6 monthsguaranteed for sterility for unopened vials stored at 2-8 degree C (guaranteedstarting from the date of delivery, replacement only)
DOTAP:1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)
DC-CHOL:DC-Cholesterol∙HCl, 3b-[N-(N",N"-dimethylaminoethane)-caramoyl]chelesterol hydrochloride
Attachment of class B CpG ODN ontoDOTAP/DC-cholliposomein nasalvaccineformulations augments antigen-specificimmuneresponses in mice.
Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.BMC Res Notes. 2017 Jan 26;10(1):68. doi: 10.1186/s13104-017-2380-8.PMID:28126014
Nasalvaccinationwith pneumococcal surface protein A in combination with cationicliposomesconsisting ofDOTAPandDC-cholconfers antigen-mediated protectiveimmunityagainst Streptococcus pneumoniae infections in mice.
Tada R, Suzuki H, Takahashi S, Negishi Y, Kiyono H, Kunisawa J, Aramaki Y.Int Immunopharmacol. 2018 Aug;61:385-393.
Comparison of the depot effect and immunogenicity ofliposomesbased on dimethyldioctadecylammonium (DDA), 3β-[N-(N",N"-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolongedliposomeretention mediates stronger Th1 responses.
Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, Perrie Y.Mol Pharm. 2011 Feb 7;8(1):153-61.
Cationic DDA/TDBliposomeas a mucosalvaccineadjuvant for uptake by dendritic cells in vitro induces potent humouralimmunity.
Qu W, Li N, Yu R, Zuo W, Fu T, Fei W, Hou Y, Liu Y, Yang J.Artif Cells Nanomed Biotechnol. 2018;46(sup1):852-860.
IntranasalImmunizationwithDOTAPCationicLiposomesCombined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and SystemicImmuneResponses in Mice.
Tada R, Hidaka A, Iwase N, Takahashi S, Yamakita Y, Iwata T, Muto S, Sato E, Takayama N, Honjo E, Kiyono H, Kunisawa J, Aramaki Y.PLoS One. 2015 Oct 6;10(10):e0139785. doi: 10.1371/journal.pone.0139785. eCollection 2015.PMID:26440657
Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K, Sundaresan A, Cheow WS.Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43.
Intranasal administration of cationicliposomesenhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity.
Tada R, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.BMC Res Notes. 2018 Jul 13;11(1):472.
Predicting the influence ofliposomallipid composition onliposomesize, zeta potential andliposome-induced dendritic cell maturation using a design of experiments approach.
Soema PC, Willems GJ, Jiskoot W, Amorij JP, Kersten GF.Eur J Pharm Biopharm. 2015 Aug;94:427-35.
Liposome-mediated DNAimmunisationvia the subcutaneous route.
Perrie Y, McNeil S, Vangala A.J Drug Target. 2003;11(8-10):555-63.
Lipoplexes formulation and optimisation: in vitro transfection studies reveal no correlation with in vivovaccinationstudies.
McNeil SE, Vangala A, Bramwell VW, Hanson PJ, Perrie Y.Curr Drug Deliv. 2010 Apr;7(2):175-87.
A new intranasal influenzavaccinebased on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.Vaccine. 2006 May 1;24(18):3990-4006.
Cationicliposomespromote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens.
Gao J, Ochyl LJ, Yang E, Moon JJ.Int J Nanomedicine. 2017 Feb 14;12:1251-1264.
Transcutaneousimmunizationby lipoplex-patch based DNAvaccinesis effectivevaccinationagainst Japanese encephalitis virus infection.
Cheng JY, Huang HN, Tseng WC, Li TL, Chan YL, Cheng KC, Wu CJ.J Control Release. 2009 May 5;135(3):242-9.
FormuMax科学公司位于加利福尼亚州北部硅谷的中心地带，是一家专业的药品配送公司，致力于满足医药/生物技术、化妆品和保健工业的配方开发外包的日益增长的需求。经营理念是成为**的伙伴，作为药物交付的***，特别是在制定具有挑战性的化合物脂质体和其他新的纳米技术。FormuMax拥有一支技术团队，在药物递送领域拥有***的专业知识，特别关注脂质体和其他基于脂质的技术。它们目前提供基础研究，配方可行性，定制配方准备，配方表征和分析科学的合同服务。FormuMax是**家提供大量预成型脂质体试剂的在线商店。已经成功地为来自世界各地的大学实验室、研究中心和各种行业的客户提供了服务和/或产品。
FormuMax供应主要产品：
Clophosome-氯膦酸盐脂质体
FormuMax提供两种预埋有氯磷酸盐分子的中性脂质体产品，该产品单次静脉或腹腔注射后可在脾脏经巨噬细胞清除率可达80-90%，并具有高度活性、稳定的理化性质（长期冰箱存放后仍保持均一性及悬浮特性），粘滞度低使用简便，适用于静脉、腹腔、皮下、鼻腔、气管等多种方式给药。
Doxoves-盐酸多柔比星脂质体
FormuMax可提供脂质定制的盐酸多柔比星脂质体（定制内容为脂质成分及脂质体大小）。FormuMax提供的产品为Doxoves，具有高度的产品稳定性和一致性,紧密的粒径分布和高效的药物包埋效率（高达4.0mg/mL(40mMlipid)的包埋药物浓度）。Doxoves系列产品在产品特性、稳定性及药代动力学特性上可媲美商业产品Doxil。
DrugLoadedliposomes
FormuMax提供多款包埋活性药物的脂质体产品，包括DoxorubicinHCl（含2.0mg/mL及4.0mg/mL两种浓度），IrinotecanHCl(2.0mg/mL)，TopotecanHCl(2.0mg/mL)，产品线仍在持续更新中。
预制脂质体
FormuMax供应的预制脂质体产品囊括多种通用的脂质体类型，使用世界*的优质脂类原料。该系列产品易于使用，稳定性、可靠性及可重复性高，节省时间和成本，并可为研究人员提供定制脂质体服务。目前FormuMax提供聚乙二醇化/非聚乙二醇化的常用脂质体，以及含浓度梯度Ammonium的脂质体
阳离子脂质体
FormuMax供应一系列的阳离子脂质体，用于需带正电荷的脂质体或细胞转染质粒DNA、反义/干扰RNA等。
荧光脂质体
FormuMax供应预制荧光标记的脂质体，包括常规荧光脂质体、生物素化的荧光脂质体以及Avdinized化的荧光脂质体，另外还提供客户定制的荧光脂质体（脂类及染料可选）。
脂质体制备薄膜
FormuMax供应一系列不同规格的聚碳酸酯薄膜，用于脂质体挤出制备。
ebiomall.com
